INmune Bio’s Alzheimer’s drug falls short of mid-stage study goal, shares tumble
(Reuters) -INmune Bio (INMB) said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early ...
Read moreDetails(Reuters) -INmune Bio (INMB) said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early ...
Read moreDetails
